COT-17 EFFECT OF BEVACIZUMAB AGAINST CYSTIC COMPONENT OF PRIMARY/METASTATIC BRAIN TUMORS

BACKGROUND: Bevacizumab (BEV) improves the symptom via reducing the peritumoral edema and sometimes via reducing the size of brain tumor. However,the effect of BEV against cystic part of brain tumor has not been documented yet. In this report,we investigated the effect of BEV on cystic component of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Yamasaki, Fumiyuki, Takano, Motoki, Yonezawa, Ushio, Taguchi, Akira, Onishi, Shumpei, Kurisu, Kaoru, Sugiyama, Kazuhiko
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213219/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.197
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados